During the past decade, The Institute of Oncology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "The Institute of Oncology" are "Breast Cancer" (1 trials), "Breast Neoplasm" (1 trials), "Carcinoma, Ductal, Breast" (1 trials) and "Ovarian Neoplasms" (1 trials). Many other conditions were trialed in "The Institute of Oncology" in a lesser frequency.

Most popular intervention types in "The Institute of Oncology" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Anetumab ravtansine (BAY94-9343)" (1 trials), "Fulvestrant" (1 trials), "G1T38" (1 trials) and "Pegylated Liposomal Doxorubicin" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Institute of Oncology" are 1 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "The Institute of Oncology". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in The Institute of Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in The Institute of Oncology, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".